Fidia launches new HYALONE website in Russia

Fidia Pharma Russia is pleased to announce the launch of its new Hyalone website, after the recent introduction of Hyalone in the Russian market.

The site (in Russian language) is designed to provide both doctors and patients with complete and reliable information and other helpful insights on Hyalone. The company's objective is to provide Russian visitors with an easier way to learn about Hyalone and to browse information about its application in hip and knee osteoarthritis.

Fidia's wholly-owned affiliate in Russia will be updating the website's content with useful information and articles, and wishes to establish this portal as a source of information for those who wish to know more about the company's intra-articular products based on hyaluronic acid.


Find out more about Fidia’s product portfolio:

Go to the website


Fidia Farmaceutici has a specific module dedicated to Pharmaco-Vigilance in order to promptly reporting of suspected adverse reactions. If you suspect that you have had an adverse reaction while taking one of our products or you have found defects

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint care
- ophthalmology
- active wound care
- neuroscience
- aesthetic medicine